Jordana B Cohen1, Sarah J Schrauben1, Lei Zhao2, Michael D Basso2, Mary Ellen Cvijic2, Zhuyin Li2, Melissa Yarde2, Zhaoqing Wang2, Priyanka T Bhattacharya3, Diana A Chirinos4, Stuart Prenner5, Payman Zamani5, Dietmar A Seiffert2, Bruce D Car2, David A Gordon2, Kenneth Margulies5, Thomas Cappola5, Julio A Chirinos6. 1. Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Bristol-Myers Squibb Company, Lawrenceville, New Jersey. 3. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hospital Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 5. Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 6. Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: julio.chirinos@uphs.upenn.edu.
Abstract
OBJECTIVES: This study sought to assess if clinical phenogroups differ in comprehensive biomarker profiles, cardiac and arterial structure/function, and responses to spironolactone therapy. BACKGROUND: Previous studies identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). METHODS: Among TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial) participants, we performed latent-class analysis to identify HFpEF phenogroups based on standard clinical features and assessed differences in multiple biomarkers measured from frozen plasma; cardiac and arterial structure/function measured with echocardiography and arterial tonometry; prognosis; and response to spironolactone. RESULTS: Three HFpEF phenogroups were identified. Phenogroup 1 (n = 1,214) exhibited younger age, higher prevalence of smoking, preserved functional class, and the least evidence of left ventricular (LV) hypertrophy and arterial stiffness. Phenogroup 2 (n = 1,329) was older, with normotrophic concentric LV remodeling, atrial fibrillation, left atrial enlargement, large-artery stiffening, and biomarkers of innate immunity and vascular calcification. Phenogroup 3 (n = 899) demonstrated more functional impairment, obesity, diabetes, chronic kidney disease, concentric LV hypertrophy, high renin, and biomarkers of tumor necrosis factor-alpha-mediated inflammation, liver fibrosis, and tissue remodeling. Compared with phenogroup 1, phenogroup 3 exhibited the highest risk of the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest (hazard ratio [HR]: 3.44; 95% confidence interval [CI]: 2.79 to 4.24); phenogroups 2 and 3 demonstrated similar all-cause mortality (phenotype 2 HR: 2.36; 95% CI: 1.89 to 2.95; phenotype 3 HR: 2.26, 95% CI: 1.77 to 2.87). Spironolactone randomized therapy was associated with a more pronounced reduction in the risk of the primary endpoint in phenogroup 3 (HR: 0.75; 95% CI: 0.59 to 0.95; p for interaction = 0.016). Results were similar after excluding participants from Eastern Europe. CONCLUSIONS: We identified important differences in circulating biomarkers, cardiac/arterial characteristics, prognosis, and response to spironolactone across clinical HFpEF phenogroups. These findings suggest distinct underlying mechanisms across clinically identifiable phenogroups of HFpEF that may benefit from different targeted interventions.
RCT Entities:
OBJECTIVES: This study sought to assess if clinical phenogroups differ in comprehensive biomarker profiles, cardiac and arterial structure/function, and responses to spironolactone therapy. BACKGROUND: Previous studies identified distinct subgroups (phenogroups) of patients with heart failure with preserved ejection fraction (HFpEF). METHODS: Among TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial) participants, we performed latent-class analysis to identify HFpEFphenogroups based on standard clinical features and assessed differences in multiple biomarkers measured from frozen plasma; cardiac and arterial structure/function measured with echocardiography and arterial tonometry; prognosis; and response to spironolactone. RESULTS: Three HFpEFphenogroups were identified. Phenogroup 1 (n = 1,214) exhibited younger age, higher prevalence of smoking, preserved functional class, and the least evidence of left ventricular (LV) hypertrophy and arterial stiffness. Phenogroup 2 (n = 1,329) was older, with normotrophic concentric LV remodeling, atrial fibrillation, left atrial enlargement, large-artery stiffening, and biomarkers of innate immunity and vascular calcification. Phenogroup 3 (n = 899) demonstrated more functional impairment, obesity, diabetes, chronic kidney disease, concentric LV hypertrophy, high renin, and biomarkers of tumor necrosis factor-alpha-mediated inflammation, liver fibrosis, and tissue remodeling. Compared with phenogroup 1, phenogroup 3 exhibited the highest risk of the primary endpoint of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest (hazard ratio [HR]: 3.44; 95% confidence interval [CI]: 2.79 to 4.24); phenogroups 2 and 3 demonstrated similar all-cause mortality (phenotype 2 HR: 2.36; 95% CI: 1.89 to 2.95; phenotype 3 HR: 2.26, 95% CI: 1.77 to 2.87). Spironolactone randomized therapy was associated with a more pronounced reduction in the risk of the primary endpoint in phenogroup 3 (HR: 0.75; 95% CI: 0.59 to 0.95; p for interaction = 0.016). Results were similar after excluding participants from Eastern Europe. CONCLUSIONS: We identified important differences in circulating biomarkers, cardiac/arterial characteristics, prognosis, and response to spironolactone across clinical HFpEFphenogroups. These findings suggest distinct underlying mechanisms across clinically identifiable phenogroups of HFpEF that may benefit from different targeted interventions.
Authors: Stuart J Pocock; Cono A Ariti; John J V McMurray; Aldo Maggioni; Lars Køber; Iain B Squire; Karl Swedberg; Joanna Dobson; Katrina K Poppe; Gillian A Whalley; Rob N Doughty Journal: Eur Heart J Date: 2012-10-24 Impact factor: 29.983
Authors: Julio A Chirinos; Timothy S Phan; Amer A Syed; Zeba Hashmath; Harry G Oldland; Maheswara R Koppula; Ali Tariq; Khuzaima Javaid; Rachana Miller; Swapna Varakantam; Anjaneyulu Dunde; Vadde Neetha; Scott R Akers Journal: Circ Cardiovasc Imaging Date: 2017-06 Impact factor: 7.792
Authors: Jasper Tromp; Li Shen; Pardeep S Jhund; Inder S Anand; Peter E Carson; Akshay S Desai; Christopher B Granger; Michel Komajda; Robert S McKelvie; Marc A Pfeffer; Scott D Solomon; Lars Køber; Karl Swedberg; Michael R Zile; Bertram Pitt; Carolyn S P Lam; John J V McMurray Journal: J Am Coll Cardiol Date: 2019-08-06 Impact factor: 24.094
Authors: Douglas S Lee; Philimon Gona; Ramachandran S Vasan; Martin G Larson; Emelia J Benjamin; Thomas J Wang; Jack V Tu; Daniel Levy Journal: Circulation Date: 2009-06-08 Impact factor: 29.690
Authors: Timothy S Phan; John K-J Li; Patrick Segers; Maheswara Reddy-Koppula; Scott R Akers; Samuel T Kuna; Thorarinn Gislason; Allan I Pack; Julio A Chirinos Journal: J Am Heart Assoc Date: 2016-08-29 Impact factor: 5.501
Authors: Edith Jones; E Benjamin Randall; Scott L Hummel; David M Cameron; Daniel A Beard; Brian E Carlson Journal: J Physiol Date: 2021-10-18 Impact factor: 5.182
Authors: Michael S Sabbah; Ahmed U Fayyaz; Simon de Denus; G Michael Felker; Barry A Borlaug; Surendra Dasari; Rickey E Carter; Margaret M Redfield Journal: Circ Heart Fail Date: 2020-07-29 Impact factor: 8.790
Authors: Adam G Goodwill; Hana E Baker; Gregory M Dick; Patricia E McCallinhart; Chastidy A Bailey; Scott M Brown; Joshua J Man; Darla L Tharp; Hannah E Clark; Bianca S Blaettner; Iris Z Jaffe; Douglas K Bowles; Aaron J Trask; Johnathan D Tune; Shawn B Bender Journal: Basic Res Cardiol Date: 2021-05-20 Impact factor: 17.165
Authors: Tobias Schupp; Max von Zworowsky; Linda Reiser; Mohammad Abumayyaleh; Kathrin Weidner; Kambis Mashayekhi; Thomas Bertsch; Mohammed L Abba; Ibrahim Akin; Michael Behnes Journal: Pharmacology Date: 2021-12-08 Impact factor: 2.547
Authors: Virginia S Hahn; Hildur Knutsdottir; Xin Luo; Kenneth Bedi; Kenneth B Margulies; Saptarsi M Haldar; Marina Stolina; Jun Yin; Aarif Y Khakoo; Joban Vaishnav; Joel S Bader; David A Kass; Kavita Sharma Journal: Circulation Date: 2020-10-29 Impact factor: 29.690